Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Materials Select Sector SPDR Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while Materials Select Sector SPDR Fund trades at $50.68. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | XLB | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $53.62 |
52-Week Low | $278.09 | $42.23 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $50.89 with a 1.21% daily gain. Technical indicators signal a bearish trend with moving averages showing sell pressure, while oscillators remain neutral. Recent news highlights materials sector capital inflows and geopolitical impacts on supply chains. The ETF provides diversified exposure to U.S. materials companies, with a dividend scheduled for June 2026.
Outlook remains cautious due to bearish technicals and geopolitical sensitivity. Investment appeal hinges on sector earnings growth potential amid inflation and supply disruptions. Key risks include macroeconomic volatility and concentrated sector exposure, requiring careful risk assessment for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
